Molecular Diagnostics Pharmacogenomics Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook 2026-2030

Molecular diagnostics in pharmacogenomics involves the use of DNA-based tests to determine how an individual's genetic makeup affects their response to specific drugs, supporting the broader shift toward personalized and precision medicine. The market includes products such as genotyping kits, reagents, and laboratory testing services that help clinicians select the most effective medications and dosages for individual patients. With a 2025 valuation of approximately $749 million, the market sits within the broader pharmacogenomics sector, which is valued at several billion dollars and spans companion diagnostics, genetic screening, and therapeutic drug monitoring.

• •Market valued at approximately $749 million in 2025
• •Expected CAGR of 6.82% through the forecast period
• •Applications span oncology, psychiatry, cardiology, and other therapeutic areas

The accelerating adoption of precision medicine by healthcare providers and payers is a primary catalyst, as clinical evidence mounts that genetically guided therapy improves patient outcomes and reduces adverse drug reactions. Technological advancements in next-generation sequencing, polymerase chain reaction, and microarray platforms have significantly reduced the cost and turnaround time of genetic testing, making pharmacogenomics more accessible in routine clinical practice. Additionally, regulatory agencies including the FDA have been increasingly approving companion diagnostics that must be used alongside targeted therapies, creating a strong institutional demand signal.

• •Growing emphasis on precision medicine and personalized drug therapy
• •Advancements in NGS, PCR, and microarray technologies lowering testing costs
• •Increasing FDA and regulatory approvals for companion diagnostics

The market is typically segmented by product into kits and assays, reagents and consumables, and laboratory services, with kits and reagents representing the largest revenue share due to recurring demand in clinical laboratories. By therapeutic area, oncology leads the market, driven by the proliferation of targeted cancer therapies and the requirement for biomarker testing to guide treatment selection. Regionally, North America commands the largest market share due to advanced healthcare infrastructure, favorable reimbursement policies, and high adoption of genomic medicine, while Asia-Pacific is expected to exhibit the fastest growth rate as healthcare spending rises and genomic research expands.

• •Products segmented into kits & assays, reagents, and testing services
• •Oncology is the dominant therapeutic area segment
• •North America leads in market share; Asia-Pacific is the fastest-growing region

What are the recent trends and outlook?

The market is moving toward point-of-care pharmacogenomic testing, with emerging rapid genotyping platforms capable of delivering results in hours rather than days, enabling bedside clinical decision-making. Artificial intelligence and machine learning are increasingly being applied to interpret complex genetic data and predict drug responses across diverse patient populations. The expanding pipeline of biologics and targeted therapies is expected to sustain demand for companion diagnostics, while integration of pharmacogenomic data into electronic health records is anticipated to normalize genetic testing as a standard component of medication management.

• •Point-of-care and rapid genotyping platforms gaining clinical traction
• •AI and machine learning increasingly used for drug-gene interaction interpretation
• •Growing pipeline of targeted therapies driving long-term demand for companion diagnostics